Skip to main content
. Author manuscript; available in PMC: 2017 Aug 24.
Published in final edited form as: J Biomed Nanotechnol. 2017 Apr;13(4):355–366. doi: 10.1166/jbn.2017.2353

Figure 14.

Figure 14

Cell viability (MDA-MB-231 triple negative breast cancer) determined by WST assay (cell proliferation). There was significantly decreased viability in cells treated with PCL +Paclitaxel, PCL +5FU, and PCL +Paclitaxel+5FU.